松脂醇二葡萄糖苷对生长期大鼠骨质量的影响

谢高倩; 高玉海; 柏鑫; 何玥颖; 陈克明

doi:10.16016/j.2097-0927.202107081

您当前的位置：

首页 >

文章列表页 >

松脂醇二葡萄糖苷对生长期大鼠骨质量的影响

基础医学 | 更新时间：2026-01-09

- 松脂醇二葡萄糖苷对生长期大鼠骨质量的影响
- Effect of pinoresinol diglucoside on bone quality in growing rats
- 陆军军医大学学报 2022年44卷第2期页码：132-137
- 作者机构：
  
  1.730070 兰州，甘肃农业大学生命科学技术学院
  2.730050 兰州，中国人民解放军联勤保障部队第九四○医院基础医学实验室
- 作者简介：
  
  [ 陈克明，E-mail：chenkm@lut.cn CHEN Keming, E-mail: chenkm@lut.cn
- 基金信息：
  
  国家自然科学基金面上项目(81770879);军队后勤科研计划(CLB18J028);联勤保障部队第九四○医院青年培育项目(2021yxky053)
- DOI：10.16016/j.2097-0927.202107081
  中图分类号： R285.5;R322.71;R681.01
- 收稿：2021-07-12，
  
  修回：2021-10-09，
  
  纸质出版：2022-01-30
- 稿件说明：
移动端阅览
谢高倩, 高玉海, 柏鑫, 等. 松脂醇二葡萄糖苷对生长期大鼠骨质量的影响[J]. 陆军军医大学学报, 2022,44(2):132-137.

Gaoqian XIE, Yuhai GAO, Xin BAI, et al. Effect of pinoresinol diglucoside on bone quality in growing rats[J]. Journal of Army Medical University, 2022, 44(2): 132-137.
谢高倩, 高玉海, 柏鑫, 等. 松脂醇二葡萄糖苷对生长期大鼠骨质量的影响[J]. 陆军军医大学学报, 2022,44(2):132-137. DOI： 10.16016/j.2097-0927.202107081.

Gaoqian XIE, Yuhai GAO, Xin BAI, et al. Effect of pinoresinol diglucoside on bone quality in growing rats[J]. Journal of Army Medical University, 2022, 44(2): 132-137. DOI： 10.16016/j.2097-0927.202107081.

摘要

目的

研究松脂醇二葡萄糖苷(pinoresinol diglucoside

PDG)对生长期大鼠骨质量的影响

评价其应用于抗骨质疏松药物的潜力。

方法

将30只1月龄雌性SD大鼠按随机数字表法分为3组: 对照组(Control)、25 mg/(kg·d)的PDG处理组(PDG-25)和50 mg/(kg·d)的PDG处理组(PDG-50)

体质量(107±7)g

每组10只。Control组每天灌服等体积蒸馏水

PDG-25组和PDG-50组分别每天灌服25 mg/kg和50 mg/kg的PDG。第2、4、6周后检测大鼠全身骨密度。之后处死所有大鼠

计算重要器官的器官系数

进行micro CT扫描、骨生物力学实验以及血清骨代谢生化指标检测等。

结果

各组大鼠体质量和主要器官系数差异无统计学意义; 6周时PDG-25组和PDG-50组的全身骨密度均显著高于Control组(

0.05);PDG-50组的相对骨体积、骨小梁数和体积骨密度显著高于Control组(

0.05)

骨小梁分离度显著低于Control组(

0.05)

PDG-25组和PDG-50组的骨微结构均明显优于Control组; PDG-50组的股骨弹性模量和椎骨最大载荷显著高于Control组(

0.05);PDG-50组血清骨钙素含量显著高于Control组(

0.01)

但血清抗酒石酸酸性磷酸酶5b含量显著低于Control组(

0.01)

PDG-25组血清骨钙素含量显著高于Control组(

0.05)。

结论

PDG能有效提高生长期大鼠的骨密度、优化骨微结构、增强骨强度、促进骨形成的同时抑制骨吸收

提高骨质量。

Abstract

Objective

To determine the effect of pinoresinol diglucoside (PDG) on bone quality in growing rats and evaluate its potential as an anti-osteoporosis drug.

Methods

A total of 30 1-month-old female SD rats (body weight 107±7 g) were randomly divided into 3 groups: control group (Control)

25 mg/(kg·d) PDG treatment group (PDG-25) and 50 mg/(kg·d) PDG treatment group (PDG-50)

with 10 rats in each group. The rats in the PDG-25 group and PDG-50 group were given corresponding doses of PDG intragastrically every day

and those of the control group was given equal volume distilled water. Their body mineral density (BMD) of the whole body was measured in 2

4 and 6 weeks after treatment. In the end of 6 weeks

all rats were sacrificed

and organ coefficients of important organs were calculated. Micro-CT scanning

bone biomechanical test and serum biochemical tests of bone metabolism were performed.

Results

There were no significant differences in body weight and main organ coefficients among the groups. At 6 weeks

the BMD value was significantly higher in the PDG-25 group and PDG-50 group than the Control group (

0.05). The PDG-50 group had significantly higher relative bone volume

trabecular number and volumetric bone mineral density (

0.05)

lower trabecular separation (

0.05) than the Control group

and the bone microstructure of PDG-25 group and PDG-50 group was significantly better than that of Control group. The PDG-50 group had elevated elastic modulus of femur (

0.05)

larger maximum load of vertebrae (

0.0

5). The PDG-50 group had increased content of serum osteocalcin (

0.01)

but obviously lower content of serum tartrate resistant acid phosphatase 5b (

0.01)

when compared with the Control group. The content of serum osteocalcin in the PDG-25 group was significantly higher than that in the Control group (

0.05).

Conclusion

PDG can effectively improve bone mineral density

optimize bone microstructure

enhance bone strength

promote bone formation

inhibit bone resorption and improve bone quality.

关键词

Keywords

references

JOHNSTON C B, DAGAR M. Osteoporosis in older adults[J]. Med Clin North Am, 2020, 104(5): 873-884. DOI: 10.1016/j.mcna.2020.06.004.

ASPRAY T J, HILL T R. Osteoporosis and the ageing skeleton[J]. Subcell Biochem, 2019, 91: 453-476. DOI: 10.1007/978-981-13-3681-2_16.

LIU Y X, LIU J P, XIA Y. Chinese herbal medicines for treating osteoporosis[J]. Cochrane Database Syst Rev, 2014(3): CD005467. DOI: 10.1002/14651858.CD005467.pub2.

隋雨婷, 李乐乐, 刘俊业, 等. 大豆异黄酮药理作用研究进展[J]. 吉林医药学院学报, 2019, 40(4): 293-296. DOI: 10.13845/j.cnki.issn1673-2995.2019.04.021.

SUI Y T, LI L L, LIU J Y, et al . Research progress of soy isoflavone's extract and pharmacological effects[J ] . J Jilin Med Univ, 2019, 40(4): 293-296. DOI: 10.13845/j.cnki.issn1673-2995.2019.04.021.

施洋, 候宝林, 吴胜利, 等. 植物雌激素的研究进展[J]. 亚太传统医药, 2019, 15(11): 172-176.

SHI Y, HOU B L, WU S L, et al . Research advancement of phytoestrogen[J ] . Asia-Pac Tradit Med, 2019, 15(11): 172-176.

吴思敏, 孙薇, 高玉海, 等. 松脂醇二葡萄糖苷促进体外培养成骨细胞骨形成的作用研究[J]. 解放军医药杂志, 2021, 33(5): 9-12.

WU S M, SUN W, GAO Y H, et al . Effect of pinoresinol diglucoside on bone formation of osteoblasts in vitro [J ] . Med Pharm J Chin PLA, 2021, 33(5): 9-12..

LANGDAHL B L. Overview of treatment approaches toosteoporosis[J]. Br J Pharmacol, 2021, 178(9): 1891-1906. DOI: 10.1111/bph.15024.

ZHU X, ZHENG H. Factors influencing peak bone massgain[J]. Front Med, 2021, 15(1): 53-69. DOI: 10.1007/s11684-020-0748-y.

王桂云, 刘湘琳, 陈沙, 等. 中医药治疗骨质疏松症的研究进展[J]. 湖南中医杂志, 2020, 36(6): 162-165. DOI: 10.16808/j.cnki.issn1003-7705.2020.06.064.

WANG G Y, LIU X L, CHEN S, et al . Research progress of traditional Chinese medicine in the treatment of osteoporosis[J ] . Hunan J Tradit Chin Med, 2020, 36(6): 162-165. DOI: 10.16808/j.cnki.issn1003-7705.2020.06.064.

ZHANG R, LIU Z G, LI C, et al . Du-Zhong (Eucommia ulmoides Oliv. ) cortex extract prevent OVX-induced osteoporosis in rats[J ] . Bone, 2009, 45(3): 553-559. DOI: 10.1016/j.bone.2008.08.127.

ZHANG R, PAN Y L, HU S J, et al . Effects of total lignans from Eucommia ulmoides barks prevent bone loss in vivo and in vitro [J ] . J Ethnopharmacol, 2014, 155(1): 104-112. DOI: 10.1016/j.jep.2014.04.031..

刘锟, 潘颖宜, 王健英, 等. 杜仲化学成分的主要影响因素概况[J]. 中国医药导报, 2020, 17(12): 41-44.

LIU K, PAN Y Y, WANG J Y, et al . Research on the main factors affecting the chemical composition of eucommia ulmoides Oliv[J ] . China Med Her, 2020, 17(12): 41-44.

HERNANDEZ-BECERRA E, LONDOÑO-RESTREPO S M, HERNÁNDEZ-URBIOLA M I, et al . Determination of basal bone mineral density in the femur bones of male and female Wistar rats[J ] . Lab Animals, 2021, 55(1): 30-42. DOI: 10.1177/0023677220922566.

JEPSEN K J, SCHLECHT S H. Biomechanical mechanisms: resolving the apparent conundrum of why individuals with type Ⅱ diabetes show increased fracture incidence despite having normal BMD[J]. J Bone Miner Res, 2014, 29(4): 784-786. DOI: 10.1002/jbmr.2189.

CHEN J, CHEN P, QI H, et al . Puerarin affects bone biomarkers in the serum of rats with intrauterine growth restriction[J ] . J Tradit Chin Med, 2016, 36(2): 211-216. DOI: 10.1016/s0254-6272(16)30029-2.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

模拟微种植体植入上颌后牙区外周骨密度的锥形束CT测量分析

外源性甲状旁腺素对小鼠骨折愈合的影响

老年2型糖尿病瘦素、骨密度变化及相关因素的研究